💬 “It’s a chicken-and-egg problem.”

Andreas Ingemann Jensen, CEO of TetraKit Technologies explains how developing a breakthrough treatment with Astatine-211 requires building the drug and its supply chain at the same time.

📽️ In this short video, discover how TetraKit contributes to Accelerate.EU by pushing the boundaries of innovation in targeted alpha therapies.

Full post can be found here: https://www.linkedin.com/feed/update/urn:li:activity:7346484220988424192